Kanchan Kumari1, Sudarshan Kumar2, Dillip K Parida3, Sandip K Mishra4. 1. Cancer Biology Laboratory, Institute of Life Sciences, Department of Biotechnology (Govt. of India), Bhubaneswar, Odisha, India. 2. Animal Biotechnology Center, National Dairy Research Institute, Karnal, Haryana, India. 3. Department of Radiation Oncology, All India Institute of Medical Sciences, Bhubaneswar, 751019, India. 4. Cancer Biology Laboratory, Institute of Life Sciences, Department of Biotechnology (Govt. of India), Bhubaneswar, Odisha, India. sandipkmishra@hotmail.com.
Abstract
BACKGROUND: Acquired resistance to drug involves multilayered genetic and epigenetic regulation. Inhibition of EZH2 has proven to reverse the tamoxifen resistance back to the sensitive state in breast cancer. However, the molecular players involved in EZH2-mediated effects on tamoxifen-resistant MCF-7 cells are unknown. This study was conducted to understand the global change in proteome profile of tamoxifen-resistant MCF-7 breast cancer cells upon EZH2 knockdown. METHODS: Tamoxifen resistance MCF-7 breast cancer cells were established using increasing concentrations of 4-hydroxy tamoxifen. Using label free proteomics approach, we studied the alteration in total proteome in resistant cells as well as cells transfected with siEZH2 in comparison to sensitive and cells transfected with non-targeting siRNA. RESULTS: Here, we report list of proteins that were previously not recognized for their role in tamoxifen resistance and hold a close association with breast cancer patient survival. Proteins Annexin A2, CD44, nucleosome assembly protein 1, and lamin A/C were among the most upregulated protein in tamoxifen-resistant cells that were found to be abrogated upon EZH2 knockdown. The study suggests the involvement for various proteins in acquiring resistance towards tamoxifen and anticipates further research for investigating their therapeutic potentials. CONCLUSION: Overall, we propose that targeting EZH2 or the molecules down the cascade might be helpful in reacquiring sensitivity to tamoxifen in breast cancer.
BACKGROUND: Acquired resistance to drug involves multilayered genetic and epigenetic regulation. Inhibition of EZH2 has proven to reverse the tamoxifen resistance back to the sensitive state in breast cancer. However, the molecular players involved in EZH2-mediated effects on tamoxifen-resistant MCF-7 cells are unknown. This study was conducted to understand the global change in proteome profile of tamoxifen-resistant MCF-7 breast cancer cells upon EZH2 knockdown. METHODS:Tamoxifen resistance MCF-7 breast cancer cells were established using increasing concentrations of 4-hydroxy tamoxifen. Using label free proteomics approach, we studied the alteration in total proteome in resistant cells as well as cells transfected with siEZH2 in comparison to sensitive and cells transfected with non-targeting siRNA. RESULTS: Here, we report list of proteins that were previously not recognized for their role in tamoxifen resistance and hold a close association with breast cancerpatient survival. Proteins Annexin A2, CD44, nucleosome assembly protein 1, and lamin A/C were among the most upregulated protein in tamoxifen-resistant cells that were found to be abrogated upon EZH2 knockdown. The study suggests the involvement for various proteins in acquiring resistance towards tamoxifen and anticipates further research for investigating their therapeutic potentials. CONCLUSION: Overall, we propose that targeting EZH2 or the molecules down the cascade might be helpful in reacquiring sensitivity to tamoxifen in breast cancer.
Authors: E A Reijm; M P H M Jansen; K Ruigrok-Ritstier; I L van Staveren; M P Look; M E Meijer van Gelder; A M Sieuwerts; S Sleijfer; J A Foekens; E M J J Berns Journal: Breast Cancer Res Treat Date: 2010-03-20 Impact factor: 4.872
Authors: Janice M Knowlden; Iain R Hutcheson; Helen E Jones; Tracieann Madden; Julia M W Gee; Maureen E Harper; Denise Barrow; Alan E Wakeling; Robert I Nicholson Journal: Endocrinology Date: 2003-03 Impact factor: 4.736
Authors: E A Reijm; A M Timmermans; M P Look; M E Meijer-van Gelder; C K Stobbe; C H M van Deurzen; J W M Martens; S Sleijfer; J A Foekens; P M J J Berns; M P H M Jansen Journal: Ann Oncol Date: 2014-09-05 Impact factor: 32.976
Authors: Changhua Zhou; Qiu Zhong; Lyndsay V Rhodes; Ian Townley; Melyssa R Bratton; Qiang Zhang; Elizabeth C Martin; Steven Elliott; Bridgette M Collins-Burow; Matthew E Burow; Guangdi Wang Journal: Breast Cancer Res Date: 2012-03-14 Impact factor: 6.466
Authors: Belinda J Petri; Kellianne M Piell; Gordon C South Whitt; Ali E Wilt; Claire C Poulton; Norman L Lehman; Brian F Clem; Matthew A Nystoriak; Marcin Wysoczynski; Carolyn M Klinge Journal: Cancer Lett Date: 2021-07-14 Impact factor: 9.756